23948sdkhjf

They’re all doing it – buying drug research

| Av Boel Jönsson | Tipsa redaktionen

December 12 the time has come for this year's annual partnering meeting Pharma Outsourcing in Stockholm. In Sweden this is a growing business, with Recipharm as the biggest CRMO of the country.

According to a report from the Swedish Agency for Growth Policy Analysis, contract research and manufacturing organisations (CRMOs) are among those with the fastest growth in terms of number of employees and net turnover. The business segment that has seen the fastest rise in employment figures during the past ten years is that of the contract manufacturing organisations (CMOs).

Sweden’s biggest CRMO is Recipharm, which is also one of the biggest in Europe. According to Torkel Gren, the company’s Science and Technology Officer, the service sector’s increased growth can be attributed mainly to the fast pace of advancements in research.

– These result in new technology and new methods that can act as tools for product development. However, in every project you need access to the right expertise, technology and methods in order for a complex process such as drug development to function. Contract research enables even small and medium-sized companies to gain such access.

The service companies enable the customers (pharma companies) to buy any services they need, and also to organise their sales structure and utilise their resources to their full potential.

– It is becoming very natural to buy R& D services today, compared with ten years ago. Even the large companies do it, says Torkel Gren.

In your experience, are pharmaceutical companies able to afford development contracts?

– I think the structure benefits the drugs companies. They would never be able to develop products without that infrastructure. Also, now you hear a lot less about companies having financing issues than you did two or three years ago.

Do you believe Sweden has a good infrastructure for drugs development?

– Yes, I do. Large sections of the development chain are present here, and the fact that they are available at close quarters is probably making things easier to handle, particularly for smaller drugs companies. We have people who understand drug development, and who are able to purchase and put together parts for an entire project. A lot of this is of course a legacy from big pharma in Sweden, but in recent years I’ve also noticed young people who have learnt by working in the system we have today, which shows that this is possible, although it requires that the individuals themselves are responsible for their own further training.

In 2017, biopharmaceuticals accounted for around 38 percent of the drugs in the research portfolios of global pharmaceutical companies, and this segment has increased heavily in recent years.

– We have seen fantastic development within biopharmaceuticals. That can easily lead to the impression that small molecule development has come to a halt, says Torkel Gren, who devotes a lot of his time to work involving small molecules.

– However, that is not the case. There is a lot of work going on based both on completely new molecules and on finding new ways of using already existing substances (new indications and methods of administration and formulation).

Although there is strong growth in biopharmaceuticals, small molecules will continue to play an important role for a long time. They have great advantages in that they are easy to administer (orally), and they are cheap to produce and handle.

– It will be a long time before we can administer biopharmaceuticals substantively in any other way than through injections.

Moreover, chemistry is evolving and today there are, for instance, numerous methods for improving the solubility and dissolution rate of small molecule substances, which are common problems. Often, such methods are based on increasing the particle surface, weakening the inter-molecular bonds, or the drugs being bonded to complexes or lipid systems.

– There are many diseases, apart from the most common ones, where small molecules would be a very good complement. A lot more work remains to be done.

Visit Pharma Outsourcing in Stockholm 12 december: Read more about it here.

Håll dig uppdaterad med Life Science Sweden
Är du prenumerant? Bli prenumerant

Med en prenumeration får du obegränsad tillgång till webbtidningen. Läs webbtidningen online.

Kommentarer (0)
Startsidan just nu

Skåne inför screening för tarmcancer

”Sverige är annorlunda på flera sätt”

Branschen saknar kompetens, samtidigt som det går arbetslösa akademiker i landet. Nu får de hjälp att finna varandra. Khady Ndoye från Senegal går Handelshögskolans program och valde praktik på Triolab.

”Vi följer den internationella debatten kring probiotika”

Bättre resultat och höjd utdelning blev facit när probiotikabolaget Biogaia kom med sitt bokslut förra veckan. Här kommenterar vd Isabelle Ducellier.

1

Ökad förlust för cancerbolaget

Gen som ger färre spermier

I studier på zebrafiskar har forskare identifierat en gen som är viktig för att producera spermier. Resultatet när genen stängs av är få och dåliga spermier. Nästa steg är att pröva om detsamma gäller hos människor.

New Updates in Drug Formulation & Bioavailability: AI hett område

Nyhetsbrev

Nätverksdag för life science – Anmälan öppen

Den 4 april är det dags för nätverksdagen the Future of Swedish & Danish Life Science i Lund för åttonde året i rad med en lång rad spännande talare och utställare.

Arkiv

AstraZeneca slår förväntningarna

Meet the governmental life science office

More clinical trials, promotion for digitisation and interoperability together with increased use of data generated by both healthcare and individuals. The duties of the Life Sciences office are plentiful.

Ska stärka kommunikationen med aktieägarna

Klimatpåverkan av inköp från läkemedelssektorn

2

Gener bidrar till narkolepsi orsakad av vaccin

Ärftliga faktorer kan öka risken att få en svår ovanlig biverkan. Detta studeras systematiskt i det nationella projektet Swedegene. En av de svåra biverkningar som studeras är narkolepsi.

Krönika: It´s time to establish relations

Communication with the patient is the key to future healthcare, writes Hanna Brodda, editor in chief of Life Science Sweden.

Svensk inkubator utvald till EU-coach

Närmare läkemedel mot ryggmärgsskada

Nyupptäckt sjukdom viktigt för diabetiker

Framgång för Gasporox

Bemis måste sälja medicinförpackningar

Ny USA-topp i Recipharm

Storslam för Moberg

Branschupprop för svensk life science

”Engagemanget finns men förutsättningarna måste komma från regeringen.” Namnkunnigt ekosystemet samlar sig bakom uppgiften att stärka Sveriges som life science-nation. Idag lämnas åtgärdsförslagen till regeringen.

Hallå där Kristina von Sydow!

...vd för E-vis som sköter arbetet med det svenska verifieringssystemet av läkemedel. Hur har det gått?

Follicum väljer kandidat

How to become globally competitive

Here Gunilla Osswald from BioArctic share her experience of scaling up and be competative on the global arena.

Spridning av RS-virus tar fart

Ny finanschef till Hansa

Emission efter försenad milstolpe

Miljardavtal mellan läkemedelsbolag

Särläkemedelsstatus lyfter kursen

Blir ny FoU-chef

Alzheimerkandidat prövas i fas III

Hon får Scheelepriset

Umeåforskare i världstoppen

Apoteksgruppen värvar chef från Ica

Särläkemedelsstatus till Bioinvent

Stora pengar till Oncopeptides

Se alla Företagens egna nyheter

Sänd till en kollega

0.123